Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Triggering receptor expressed on myeloid cells-like 5, pseudogene (TREML5P) is a non-coding genetic locus annotated as a member of the TREM (Triggering Receptor Expressed on Myeloid cells) family but classified as a **pseudogene** in humans[1]. It is also referred to as TLT5, TREM like transcript 5, TREML2P, or TREML2P1[1]. This pseudogene does not encode a functional receptor or protein, and therefore it is not a therapeutic target, has no biological function, and is not known to play any role in disease. Its inclusion in experimental or therapeutic literature would be an error, as only the four functional TREM family members—TREM-1, TREM-2, TLT1 (TREML1), and TLT2—are established as protein-coding, functional receptors[2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Triggering receptor expressed on myeloid cells-like 5, pseudogene (TREML5P).